MeSH D017086 - beta-thalassemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Deferasirox | Deferasirox Accord |  | 2020-01-09 |  |  |
| bluebird bio | Betibeglogene autotemcel | Zynteglo |  | 2022-08-17 | $70.019 M | Q2/24-Q1/25 |
| Bristol Myers Squibb | Luspatercept | Reblozyl |  | 2020-06-25 | $2,040 M | Q3/24-Q2/25 |
| Chiesi Farmaceutici | Deferiprone | Ferriprox |  | 1999-08-25 |  |  |
| Endo | Sodium phenylbutyrate | Phenylbutyrate |  | 2016-06-15 |  |  |
| Lipomed | Deferiprone | Deferiprone Lipomed |  | 2018-09-19 |  |  |
| Mylan | Deferasirox | Deferasirox Mylan |  | 2019-09-26 |  |  |
| Novartis | Deferasirox | Exjade |  | 2006-08-28 | $647 M | Q2/19-Q2/22 |
Clinical Trials
Historical Success Rate
Phase 1
55%12/22
Phase 2
54%22/41
Phase 3
60%12/20
Approved: 5Overall Success rate: 18%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use